Client News
Roquefort Therapeutics – Director/PDMR ShareholdingRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company, as detailed below:
|
Number of Ordinary Shares |
Average Price Paid Per Share |
Total Consideration Paid |
|
144,117 |
6.9 pence |
£9,942.49 |
Following the above purchase of shares, Stephen West holds an interest in 5,457,381 Company ordinary shares and 7,000,000 warrants. 4,628,485 of Mr West’s shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.
Director/PDMR Shareholding – 10:36:26 26 Jun 2023 – ROQ News article | London Stock Exchange
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.